GALASHIELS pharmaceutical company, Kyowa Kirin International, formerly ProStraken, has reported positive results from a 24 week study into the treatment of X-linked hypophosphatemia, the most common heritable form of rickets.

Patients treated with Kyowa’s burosumab product as part of the study achieved a significant improvement in stiffness and strong trends in improvements in physical function and pain.

An opinion on the product’s suitability from the European Committee for Medicinal Products for Human Use is expected this year.

Loading article content